Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) has announced a Limited Competition funding opportunity titled the Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3), aimed at enhancing translational research through collaborative efforts among multiple medical research institutions. This initiative seeks to support the development, implementation, and dissemination of innovative solutions that address urgent public health needs and promote health equity, requiring applicants to include at least three eligible organizations to foster interdisciplinary partnerships. Eligible projects can receive funding of up to $650,000 annually for a total duration of up to five years, with applications due by October 19, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-296.html.
Eligible Applicants
Other Eligible Applicants include the following: See NOFO for further eligibility criteria. Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.